Present status of sulfonylurea treatment for type 2 diabetes in Japan: Second report of a cross-sectional survey of 15,652 patients

Endocrine Journal

Volumn 57, Issue 6, 2010, Pages 499-507

  Arai, Keiko ^a   Matoba, Kiyokazu ^a   Hirao, Koich ^a   Matsuba, Ikuro ^a   Takai, Masahiko ^a   Takeda, Hiroshi ^a   Kanamori, Akira ^a   Yamauchi, Mikio ^b   Mori, Hisao ^a   Terauchi, Yasuo ^c  

^a Japanese Medical and Dental Practitioners for the Improvement of Medical Care   (Japan)

^b Health Education Center Science Clinic   (Japan)

^c YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Cross sectional survey; General practitioner; HbA1c; Sulfonylurea; T2DM

Indexed keywords

BIGUANIDE; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLITAZONE DERIVATIVE; HEMOGLOBIN A1C; ORAL ANTIDIABETIC AGENT; SULFONYLUREA; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; SULFONYLUREA DERIVATIVE;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; BODY HEIGHT; BODY MASS; BODY WEIGHT; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DRUG USE; GENERAL PRACTITIONER; HEMOGLOBIN BLOOD LEVEL; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MEDICAL SPECIALIST; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; CLINICAL PRACTICE; DIABETES MELLITUS, TYPE 2; GENERAL PRACTICE; GLUCOSE BLOOD LEVEL; METABOLISM; MIDDLE AGED; TREATMENT OUTCOME;

AGED; BLOOD GLUCOSE; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; FAMILY PRACTICE; GLICLAZIDE; GLYBURIDE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; JAPAN; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; SULFONYLUREA COMPOUNDS; TREATMENT OUTCOME;

EID: 77954731903     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.K09E-366     Document Type: Article

References (29)

1. European Diabetes Policy Group (1999) A desktopguide to type 2 diabetes. Diabet Med 16:716-730.
2. Management of type 2 diabetes-management of bloodglucose-NICE summary. Available at http://nelh.nhs.uk/giodelinesdb/html/fulltext-guidelines/Bloodglucose.html.
3. American Diabetes Association (2004) Standards ofmedical care in diabetes. Diabetes Care 27(Suppl 1):S15-S34.
4. International Diabetes Federation. Global guidelinesfor type 2 diabetes. Available at http://www.idf.org/home
5. Horrower AD (1994) Comparison of efficiency, secondaryfailure rate and complication of sulfonylureas. JDiabetes Complications 8:201-203.
6. Stenman S, Melander PH, Groop PH, Groop LC (1993) What is the beneit of increasing the sulfonylurea dose? Ann Intern Med 118:169-172.
7. Rustenbeck L (2002) Desensitization of insulin secretion. Biochem Pharmacol 63:1921-1935.
8. Kobayashi M, Yamazaki K, Hirao K, Oishi M, Kanatsuka A, Yamauchi M, Takagi H, Kawai K (2006) The status of diabetes control and antidiabetic drugtherapy in Japan-A cross sectional survey of 17,000 patientswith diabetes mellitus (JDDM 1). Diabetes ResClin Pract 73:198-204.
9. Cohen FJ, Neslusan CA, Conclin JE, Song X (2003) Recent antihyperglycemic prescribing trends forUS privately insured patients with type 2 diabetes. Diabetes Care 26:1847-1851.
10. Boyc KS, Yurgin N, Lage MJ (2007) Trends in the prescriptionof antidiabetic medications in France: evidencefrom primary care physicians. Adv Ther 24:803-813.
11. Yurgin N, Secnil K, Lage MJ (2007) Antidiabetic prescriptionsand glycemic control in German patientswith type 2 diabetes mellitus: a retrospective databasestudy. Clin Ther 29:316-325.
12. Yoshinaga H, Kosaka K (1999) Heterogeneous relationshipof early insulin response and fasting insulinlevel with development of non-insulin-dependent diabetesmellitus in non-diabetic Japanese subjects with orwithout obesity. Diabetes Res Clin Pract 44:129-136.
13. UK Prospective Study Group (1998) Intensive bloodglucosecontrol with sulfpnylureas or insulin comparedwith conventional treatment and risk of complicationin patients with type 2 diabetes (UKPDS 33). Lancet352:837-853.
14. UK Prospective Study Group (1998) Effect of intensiveblood-glucose control with metformin on complicationsin overweight patients with type 2 diabetes(UKPDS 34). Lancet 352:854-856.
15. Derlmore S, Chiasson JL (2005) Acarbose in the preventionof cardiovascular disease in subjects with im-paired glucose tolerance and type 2 diabetes mellitus. Curr Opin Pharmacol 5:184-189.
16. Arai K, Hirao K, Matsuba I, Takai M, Matoba K, Takeda H, Kanamori A, Yamauchi M, Mori H, TerauchiY (2009) The status of glycemic control by generalpractitioners and specialists for diabetes in Japan; Across-sectional survey of 15,652 patients with diabetesmellitus. Diabetes Res Clin Pract 83:397-401.
17. Kuzuya T, Nakagawa S, Satoh J, Kanazawa Y, Iwamoto Y, Kobayashi T, Nanjo K, Sakai A, Seino Y, Ito C, Shima K, Nonaka K, Kadowaki T (2002) TheCommittee of the Japan Diabetes Society on the diagnosticcriteria of diabetes mellitus. Report of theCommittee on the classiication and diagnostic criteriaof diabetes mellitus. Diabetes Res Clin Pract 55:65-85.
18. Alberti KG, Zimmet PZ (1998) Definition, diagnosisand classiication of diabetes mellitus and its complications.Part 1: diagnosis and classiication of diabetesprovisional report of a WHO consultation. Diabet Med15:539-553.
19. Zimmerman BR (1997) Sulfonylureas. EndocrinolMetab Clin North Am 26:511-522.
20. Scheen AJ, Lefebvre PJ (1993) Pharmacologicaltreatment of obese diabetic patient. Diabetic Metab19:547-559.
21. Bugos C, Austin M, Atherton T, Viereck C (2003) Long-term treatment of type 2 diabetes mellitus withglimepiride is weight neutral: a multicentre retrospectivecohort study. Diabetologia 46:1611-1617.
22. Muller G, Satoh Y, Geisen K (1995) Extrapancreatic effectsof sulfonylureas: a comparison between glimepirideand conventional sulfonylureas. Diabetes Res ClinPract 28 supple 1: S115-137.
23. Davis SN (2004) The role of glimepiride in the effectivemanagement of type 2 diabetes. J DiabetesComplications 18:367-376.
24. Simonson DC, Kourides IA, Feinglos M, Shamoon H, Fischette CT, Gliptide Gastrointesitinal TherapeuticSystem Study Group (1997) Eficacy, safety and doseresponsesystem on glycemic control and insulin secretionin NIDDM, Results of two multicenter, randomized,placebo-controlled clinical trials. Diabetes Care20:597-606.
25. David SH, Bell MB (2004) Practical consideration andguidelines for dosing sulfonylureas as monotherapy orcombination therapy. Clinical Therapeutics 26:1714-1727.
26. Chaudhry ZW, Gannon MC, Nutiall FQ (2006) Stability of body weight in type 2 diabetes. DiabetesCare 29:493-497.
27. Hermansen K, Morthensen LS (2007) Bodyweightchanges associated with antihyperglycemic agents intype 2 diabetes mellitus. Drug Saf 30:1127-1142.
28. Vannasaeng S, Ploybutr S, Nytayanant W, Peerapatdit T, Vichayanrat A (1995) Effects of alpha-glucosidase inhibitor(acarbose) combined with sulfonylurea or sulfonylureaand metformin in treatment of non-insulin-dependentdiabetes mellitus. J Med Assoc Thai 78:578-585.
29. Negishi M, Shimomura K, Proks P, Shimomura Y, MoriM (2008) Alpha glucosidase inhibitor voglibose canprevent pioglitazone-induced body weight gain in Type2 diabetic patients. Br J Clin Pharmacol 66:318-319.